Baxter introduces Baxject needleless transfer device at International Haemophilia Congress

May 21, 2002

SEVILLE, Spain, World Federation of Haemophilia Congress, May 21, 2002 -- Baxter BioScience today announced the launch of the BAXJECT needleless transfer device (BAXJECT), a safer, faster and easier way to prepare haemophilia medication without the use of sharp needles or fear of accidental injury. The BAXJECT device reduces the time it takes to prepare Factor VIII clotting therapy for infusion, allowing patients to more freely go about their lives.

"The BAXJECT device is convenient because it eliminates the handling or transfer of filter needles when preparing Factor VIII concentrates for infusion," said Bruce Ewenstein, M.D., global medical director for haemophilia therapy, Baxter BioScience. "The whole process is safer and more streamlined, which goes a long way toward building confidence in anyone using the BAXJECT device to prepare haemophilia therapy. The device also is easy and safe enough for children to use, helping them to become more independent in managing their own condition."

Baxter acquired worldwide licensing rights for the use of the BAXJECT device in haemophilia patients in September 2001, a strategic move to further broaden the company's haemophilia franchise.

The BAXJECT device is compatible for use only with Baxter hemophilia therapies and will be introduced globally during the next six months. Initially the BAXJECT device will be available with Recombinate (recombinant antihaemophilic factor) and will eventually replace the transfer needles currently included in all packaging.

A RECOGNIZED NEED
The haemophilia community has asked for safer, faster and more convenient alternatives to preparing Factor VIII, a complicated process that is time-consuming and associated with the risk of needle-stick injury and contamination.

Needle-stick injury is an internationally recognized medical concern. The World Health Organization understands this and advocates that healthcare facilities develop standards, policies and procedures to address needle-stick injuries.

The BAXJECT device uses transfer spikes instead of sharp needles to mix medication during the Factor VIII infusion preparation, which involves mixing the Factor VIII powder with sterile water. A plastic barrier shields the transfer spikes at all times, so that the patient never comes in contact with them. Additionally, the BAXJECT device has a built-in filter device to remove non-visible particles that should not be present in the reconstituted solution.

This innovative design allows for faster self-infusion times and a process that greatly reduces the chance of accidental injury. Additionally, there are fewer needles in the home, including fewer disposed sharps that can pose potential risk for contamination and injury.

HOW BAXJECT WORKS
The convenience of the BAXJECT design is that the transfer spikes and the handle do all the work.

The first spike pierces the protective seal on the sterile water bottle and secures the BAXJECT device firmly into place. Next step is holding the water bottle, with device firmly secured, upside down so that the second, or twin spike, is facing downward. The placing of the second spike creates a vacuum that sets in motion the mixing, or reconstitution, process. A handle on the device allows the user to control flow. The final steps are filling the syringe for infusion.

ABOUT HAEMOPHILIA
Haemophilia A is caused by the absence or severe deficiency of Factor VIII, a protein in human blood critical for proper blood coagulation. More than 350,000 people worldwide have haemophilia. Patients can experience spontaneous, uncontrolled internal bleeding that often is associated with pain, debilitation, chronic joint destruction and if left untreated, the risk of death.

People with haemophilia infuse themselves with clotting factors on average three times a month, unless they are on a preventive regimen, in which case they may infuse as often as four times per week. Barring complications, clinicians today expect a near normal life expectancy for persons with haemophilia, provided that they receive proper treatment.
-end-
ABOUT BAXTER
Baxter International Inc (NYSE: BAX) is a global health care company that, through its subsidiaries, provides critical therapies for people with life-threatening conditions. Baxter's bioscience, medication delivery and renal products and services are used to treat patients with some of the most challenging medical conditions including cancer, hemophilia, immune deficiencies, infectious diseases, kidney disease and trauma.

(Baxter, Baxject and Recombinate are trademarks of Baxter International Inc. Baxter and Baxject are registered in the U.S. Patent and Trademark Office.)

This news release contains forward-looking statements that involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, actions of regulatory bodies, the impact of competitive products and pricing, and other risks detailed in the company's filings with the Securities and Exchange Commission. These forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements.

Contact Information
Europe (on-site)
Nancy Lovre +44 77 14 504 224
Joanne Fensome +44 77 30 918 466
North America
Deborah Spak +1 847 948 2349 (media)
Neville Jeharajah +1 847 948 2875 (Investor)
Mary Kay Ladone +1 847 948 3371 (Investor)

Porter Novelli

Related Medication Articles from Brightsurf:

New medication may treat underlying causes of hypertrophic cardiomyopathy
Mavacamten, a new investigational cardiac medication, may improve heart function for people with thickened heart muscle leading to obstructed blood flow through the heart, a condition known as obstructive hypertrophic cardiomyopathy.

Therapy plus medication better than medication alone in bipolar disorder
A review of 39 randomized clinical trials by scientists from UCLA and their colleagues from other institutions has found that combining the use medication with psychoeducational therapy is more effective at preventing a recurrence of illness in people with bipolar disorder than medication alone.

Kids diagnosed with ADHD often don't take medication regularly
Children diagnosed with ADHD inconsistently take their prescribed medication, going without treatment 40 per cent of the time, a new study has found.

Long-term medication for schizophrenia is safe
Researchers at Karolinska Institutet in Sweden and their colleagues in Germany, the USA and Finland have studied the safety of very long-term antipsychotic therapy for schizophrenia.

Which is more effective for treating PTSD: Medication, or psychotherapy?
A systematic review and meta-analysis led by Jeffrey Sonis, MD, MPH, of the University of North Carolina School of Medicine, finds there is insufficient evidence at present to answer that question.

ADHD medication: How much is too much for a hyperactive child?
When children with ADHD don't respond well to Methylphenidate (MPH, also known as Ritalin) doctors often increase the dose.

Pain medication use by children after common surgeries
About 400 caregivers reported pain medication use by children after common surgeries such as hernia, elbow fracture, appendectomy or adenoid removal in this study.

Bringing cancer medication safely to its destination
Treating cancer more selectively and more effectively -- this could be achieved with an innovative technology developed by teams of researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and the Ludwig-Maximilians-Universität München (LMU).

Bullying linked to student's pain medication use
In a school-based survey study of all students in grades 6, 8, and 10 in Iceland, the use of pain medications was significantly higher among bullied students even when controlling for the amount of pain they felt, as well as age, gender, and socioeconomic status.

New medication gives mice bigger muscles
Researchers from Aarhus University, Denmark, have studied a new group of medicinal products which increase the muscle- and bone mass of mice over a few weeks.

Read More: Medication News and Medication Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.